Oxytetracycline, Polymyxin B Sulfate

Verify with FDA CVM →

19 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Oxytetracycline, Polymyxin B Sulfate

Administration Routes

OphthalmicUnknown

Species Affected

Cat 10
Unknown 5
Dog 3
Human 1

Most Affected Breeds

Domestic (unspecified) 9
Unknown 6
Cat (unknown) 1
Bichon Frise 1
Shepherd Dog - German 1
Bulldog 1

Most Reported Reactions

Gel/Paste, Abnormal 4
Vomiting 3
Lack of efficacy (bacteria) - NOS 2
Convulsion 2
Vocalisation 2
Tachycardia 2
Elevated serum alkaline phosphatase (SAP) 1
Dispenser, Abnormal 1
Corneal ulcer 1
Blepharospasm 1
Uveitis 1
Ocular discharge 1

Data Summary

Metric Value
Total adverse event reports 19
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 4
Distinct breeds in reports 6
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Oxytetracycline, Polymyxin B Sulfate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 19 adverse event reports referencing Oxytetracycline, Polymyxin B Sulfate, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Oxytetracycline, Polymyxin B Sulfate. Reported administration routes include Ophthalmic, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Oxytetracycline, Polymyxin B Sulfate reports are Cat (10 reports), Unknown (5 reports), Dog (3 reports), with Cat accounting for the largest share. Within those species, Domestic (unspecified) (9), Unknown (6), Cat (unknown) (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Oxytetracycline, Polymyxin B Sulfate are Gel/Paste, Abnormal (4), Vomiting (3), Lack of efficacy (bacteria) - NOS (2), Convulsion (2). Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Oxytetracycline, Polymyxin B Sulfate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial